2024-12-25 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison and Divergence:**

Merck & Co Inc (MRK) is a pharmaceutical company.  Its cumulative return (64.72%) significantly underperformed the S&P 500 (VOO) cumulative return (120.69%) over the analyzed period. The difference is -55.97 percentage points.  This places it at the 6.9th percentile of its historical range of divergence from the S&P 500, indicating relatively underperformance compared to its historical context.  The provided alpha consistently shows negative values, suggesting underperformance relative to the market benchmark, even when considering beta, which reflects volatility relative to the S&P 500 and fluctuates considerably between 110.0 and 268.0


**2. Recent Price Movement:**

* **Closing Price:** $99.45
* **5-Day Moving Average:** $98.95
* **20-Day Moving Average:** $100.45
* **60-Day Moving Average:** $102.62

The price is slightly below its 20-day and 60-day moving averages, suggesting a potential short-term bearish trend.


**3. Technical Indicators and Expected Return:**

* **RSI:** 46.61  (Slightly below neutral, suggesting neither overbought nor oversold conditions.)
* **PPO:** -0.04 (Negative, indicating bearish momentum.)
* **20-Day Relative Divergence Change:** -0.7 (Short-term downward trend.)
* **Expected Return:** 0.0% (This indicates that, based on the provided data, the model does not expect MRK to outperform VOO over the long term (2+ years) in a buy-and-hold strategy.  Further analysis and information beyond the current data points are required to determine a more accurate expected return.)

The current price of $99.45 does not indicate any significant recent rapid upward or downward movement based on the provided moving averages.  However, additional context surrounding price movements not captured in the presented data is required for complete analysis.

**4. Recent Earnings Analysis:**

The provided earnings data shows some variability in both EPS and revenue.  While revenue generally shows growth from Q4 2023 to Q3 2024, EPS fluctuates. Note that there is a duplicate entry for 2024-11-06.  Without knowing the expected values, it's impossible to definitively identify "beats" or "misses."  A complete analysis requires access to analyst expectations.

* **Revenue Growth:**  Generally increasing but with some quarter-to-quarter variations.
* **EPS Trends:**  Inconsistent, requiring additional context for analysis.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows a generally upward trend, although there are fluctuations quarter-to-quarter. Profit margins are high but show slight downward pressure.

* **Capital and Profitability:** Equity shows growth over the period, however ROE shows high variability and a negative value in Q4 2023.  This requires deeper investigation to understand the underlying causes.

**6. News and Recent Issues:**

No recent news (within the last two days) is provided for analysis. The current market outlook and analyst opinions are missing.

**7. Overall Analysis:**

Merck (MRK) shows a history of underperformance relative to the S&P 500.  Technical indicators suggest a slightly bearish sentiment in the short term, but no significant recent price swings are apparent from the presented moving averages. Financial statements reveal high profit margins and revenue growth but some volatility in EPS and ROE. The lack of recent news and analyst opinions limits a comprehensive assessment.  More comprehensive data, including analyst expectations for earnings and a broader time frame for performance analysis, is required for a more robust and conclusive evaluation.  The provided 0.0% expected return, based on the current dataset, does not suggest long-term outperformance against the S&P 500.

**8. Disclaimer:** This analysis is based solely on the provided data.  It is not financial advice, and making investment decisions based on this information alone is risky.  Consult with a financial advisor before making any investment decisions.
